1. Glioblastoma (GBM) is a destructive and fatal tumor, and immunotherapy can help to avoid cancer recurrence and treat metastatic tumors.
2. Current strategies for drug targeting tumors are divided into two categories: chemical recognition and microenvironment response.
3. This article proposes a nitric oxide (NO)-driven zwitterionic polymer-based nanomotor that can respond to the concentration gradient of ROS/iNOS in the GBM microenvironment to achieve drug delivery through chemotaxis, as well as multi-step intervention synergy in the tumor immune cycle through its beneficial product NO released in the microenvironment of brain tumors and the loaded drug TLND.
The article is generally reliable, with clear evidence provided for each claim made throughout the text. The sources used are all from reputable journals, providing credibility to the claims made in the article. The authors also provide detailed explanations of their proposed strategy, which makes it easier for readers to understand their ideas.
However, there are some potential biases that should be noted. For example, while the authors discuss current strategies for drug targeting tumors, they focus mainly on chemical recognition strategies rather than microenvironment response strategies; this could lead readers to believe that chemical recognition strategies are more effective than microenvironment response strategies when this may not necessarily be true. Additionally, while the authors discuss possible risks associated with their proposed strategy, they do not explore any counterarguments or alternative solutions that could be used instead; this could lead readers to believe that their proposed strategy is without risk when this may not necessarily be true either.
In conclusion, while overall reliable and trustworthy, there are some potential biases present in this article that should be taken into consideration when reading it.